Last reviewed · How we verify
NCT03495336
The Effects of Unfiltered (Turkish) Coffee Consumption on Cardiovascular Risk Parameters
NA trial testing coffee abstention phase in Cardiovascular Diseases in 28 participants. Completed in 22 October 2017.
22 June 2017
Quick facts
| Lead sponsor | Eastern Mediterranean University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 28 |
| Start date | 22 March 2017 |
| Primary completion | 22 June 2017 |
| Estimated completion | 22 October 2017 |
| Sites | 1 location across Cyprus |
Drugs / interventions tested
- coffee abstention phase
- LR Coffee consumption
- DR Coffee consumption
Conditions studied
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Eastern Mediterranean University
Who can join
Adults 20 to 35, any sex, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Purpose/Objective: The aim of this study is to investigate the impact of boiled unfiltered (Turkish) coffee consumption on the plasma cardiovascular risk parameters of healthy subjects. The study also explores whether two unfiltered boiled (Turkish) coffee beverages that differ in content due to different roasting degrees will differentially affect cardiovascular biomarkers. Methods: In this crossover intervention study, healthy, nonsmoking, habitual Turkish coffee drinkers (n=28) were randomized to consume at least 3 cups of Light (LR) or Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks. Subsequent to each coffee abstinence period, both groups received the alternative intervention. After the first WO and the coffee intervention periods, anthropometric measures, blood pressure, heart rate and 13 biochemical parameters were collected and dietary records were completed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03495336
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Diseases
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT07426263 — Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation. · NA · active not recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Eastern Mediterranean University trials
Trials by the same sponsor.
- NCT07462039 — Effect of Virtual Reality on Pain and Anxiety During Pap Smear Testing · NA · not yet recruiting
- NCT07328750 — Dynamic Q Angle and Core Endurance in Adolescent Athletes With Patellofemoral Pain Syndrome · recruiting
- NCT07311005 — NURSE - LED DIGITAL EDUCATION AND BIGOREXIA · NA · enrolling by invitation
- NCT07077993 — "Muscle Strength, Balance, and Core Endurance in Elite Adolescent Rowers: A Cross-Sectional Study" · completed
- NCT06953037 — Effects of Acupressure Applied Before Cesarean Delivery on Anxiety, Physiological Parameters and Fetal Heart Rate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03495336 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eastern Mediterranean University
- Last refreshed: 12 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03495336.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing